200 related articles for article (PubMed ID: 23271779)
1. Active surveillance: the Canadian experience with an "inclusive approach".
Klotz L
J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):234-41. PubMed ID: 23271779
[TBL] [Abstract][Full Text] [Related]
2. Active surveillance: the Canadian experience.
Klotz L
Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
[TBL] [Abstract][Full Text] [Related]
3. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer.
Klotz L; Zhang L; Lam A; Nam R; Mamedov A; Loblaw A
J Clin Oncol; 2010 Jan; 28(1):126-31. PubMed ID: 19917860
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
5. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
Krakowsky Y; Loblaw A; Klotz L
J Urol; 2010 Jul; 184(1):131-5. PubMed ID: 20478589
[TBL] [Abstract][Full Text] [Related]
7. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
8. Active Surveillance for Favorable Risk Prostate Cancer in African Caribbean Men: Results of a Prospective Study.
Meunier ME; Eyraud R; Sénéchal C; Gourtaud G; Roux V; Lanchon C; Brureau L; Blanchet P
J Urol; 2017 May; 197(5):1229-1236. PubMed ID: 27993665
[TBL] [Abstract][Full Text] [Related]
9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
10. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
11. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
Klotz LH
Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance with selective delayed intervention: using natural history to guide treatment in good risk prostate cancer.
Klotz L
J Urol; 2004 Nov; 172(5 Pt 2):S48-50; discussion S50-1. PubMed ID: 15535443
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
14. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with Discontinuation of Active Surveillance among Men with Low-Risk Prostate Cancer: A Population-Based Study.
Timilshina N; Komisarenko M; Martin LJ; Cheung DC; Alibhai S; Richard PO; Finelli A
J Urol; 2021 Oct; 206(4):903-913. PubMed ID: 34412510
[TBL] [Abstract][Full Text] [Related]
17. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
18. An evidence review of active surveillance in men with localized prostate cancer.
Ip S; Dahabreh IJ; Chung M; Yu WW; Balk EM; Iovin RC; Mathew P; Luongo T; Dvorak T; Lau J
Evid Rep Technol Assess (Full Rep); 2011 Dec; (204):1-341. PubMed ID: 23126653
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
[TBL] [Abstract][Full Text] [Related]
20. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]